Selegiline Transdermal System In the Treatment of Major Depressive Disorder

  title={Selegiline Transdermal System In the Treatment of Major Depressive Disorder},
  author={J. Frampton and G. Plosker},
  • J. Frampton, G. Plosker
  • Published 2012
  • Medicine
  • Drugs
  • Abstract▴ The monamine oxidase (MAO) inhibitor selegiline is selective for MAO-B at the low oral dosages used in the treatment of Parkinson’s disease. However, MAO-A is also inhibited at the high oral dosages needed to effectively treat depression (not an approved indication), necessitating a tyramine-restricted diet. The selegiline transdermal system was designed to deliver antidepressant drug concentrations to the CNS, without substantially impairing small intestine MAO-A activity. At the… CONTINUE READING
    18 Citations
    Selegiline Transdermal System: In the Treatment of Major Depressive Disorder
    MAO-inhibitors in Parkinson's Disease
    • 140
    • PDF
    The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
    • 12
    • PDF
    3-Coumaranone derivatives as inhibitors of monoamine oxidase
    • 6
    • PDF
    Structure‐Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases
    • Riri Shi, Q. Wu, +8 authors W. Huang
    • Chemistry, Medicine
    • Chembiochem : a European journal of chemical biology
    • 2019
    • 6
    Monoamine oxidase inhibitors and neuroprotection: a review.
    • 34


    Oral Versus Transdermal Selegiline: Antidepressant-Like Activity in Rats
    • 34
    Monoamine oxidase inhibitors: a new generation.
    • 45
    Selegiline transdermal system Somerset.
    • I. Mahmood
    • Medicine
    • Current opinion in investigational drugs
    • 2002
    • 6